Regarding CHF trial and MPC-150-IM

From the company update from yesterday and this is what I see (did not want to post yesterday what with the storm of negative posters raining on here):

1. "To meet the program’s remaining funding requirements, Mesoblast has been offered an equity finance facility"
2. "Mesoblast now has unencumbered rights to partner with a leading cardiovascular company with a commitment to heart failure product commercialization"

Both those read in the past tense, in my interpretation:
"Has been offered" and "to partner with a leading cardiovascular company".
So here goes:
a) the offer for an equity finance facility is on the table from company 'x'
b) they have identified company 'y' for heart failure product commercialization

Company 'y' could very well make an UPFRONT cash payment, much like Helios paid to Athersys.
Two separate funding sources for the CHF treatment program.